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ABSTRACT

TOWARD THE TOTAL SYNTHESIS OF DRAGONAMIDE E AND ITS POTENTIAL
MEDICINAL APPLICATION AGAINST LEISHMANIASIS
Nathaniel M. Smith
Thesis Chair: Sean C. Butler, Ph.D.
The University of Texas at Tyler
July 2021
Leishmaniasis is one of the world’s most neglected tropical diseases, with hundreds
of thousands of cases occurring worldwide annually. The disease originates from being
infected by protozoa of the Leishmania genus, which are parasites that destroy mammalian
cells as part of their life cycle. Currently utilized treatment strategies for leishmaniasis have
many disadvantages, warranting the search for a new leishmaniasis treatment.
Cyanobacteria have been discovered to synthesize a wide variety of cytotoxic
chemicals as part of their own defense mechanism. One strain of cyanobacteria, Lyngbya
majuscula, produces several families of compounds, one of which is known as the
“dragonamides”. Several of the compounds in this class have activity against the
leishmania parasite, with the most efficacious one being dragonamide E.
To further understand the antileishmanial mechanism of dragonamide E, a total
synthesis is proposed so that researchers can produce dragonamide E in the lab without
having to extract it from Lyngbya majuscula. The greater availability of dragonamide E
x

due to a published synthesis route will increase the ease with which research can be done
into the antileishmanial properties of dragonamide E, promoting the development of new
and more efficacious leishmaniasis treatments.

xi

CHAPTER 1
A BRIEF OVERVIEW OF LEISHMANIASIS AND ITS SIGNIFICANCE

1.1 An Introduction to Leishmaniasis
Leishmaniasis is one of the world’s most neglected and devastating tropical
diseases, with an estimated 700,000 to 1 million new cases occurring annually.1,2 The
disease is onset by the bite of an infected female phlebotomine sandfly, which can transmit
parasitic protozoans of the Leishmania genus, hence the disease’s name.3 Once the
protozoan enters the human body, the body’s phagocytic cells encapsulate the foreign
material in an attempt to destroy it.4 However, the environment inside the phagocytic cells
is what Leishmania protozoa require to replicate.4 After the protozoan multiplies by simple
division, the phagocytic cell is lysed and releases more of the parasite into the body,
continuing the cycle.4
There are three main types of leishmaniasis: visceral, cutaneous, and
mucocutaneous.2 Visceral leishmaniasis (VL) occurs when the parasite infects vital organs,
and is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and
liver, and anemia. If left untreated, VL is the most fatal of the leishmaniasis variants.1–3
Cutaneous leishmaniasis (CL) is the most common form of the disease, which occurs when
the parasite only infects the tissue surrounding the sandfly bite. CL is characterized by
principally ulcerated skin lesions on uncovered parts of the body, thereby leaving
1

noticeable lifelong scars and serious disability.1–3 Mucocutaneous leishmaniasis (ML) is
the rarest form of the disease and is a variant of CL, where the parasite disseminates from
the original lesion via hematogenous or lymphatic pathways, resulting in partial or total
destruction of the nose, mouth, and/or throat mucous membranes.1–3

1.1.1 Worldwide Effects of Leishmaniasis
Leishmaniasis is caused by any of the 20+ known parasitic protozoans of the
Leishmania genus, so the specific strain of leishmaniasis differs by region (Figure 1.1). VL
is most common in Brazil, East Africa, and India, with an estimated 50,000–90,000 new
cases occurring annually. In 2018, more than 95% of new VL cases reported to the World
Health Organization (WHO) occurred in ten countries: Brazil, China, Ethiopia, India, Iraq,
Kenya, Nepal, Somalia, South Sudan, and Sudan.2 About 95% of CL cases occur in the
Americas, the Mediterranean basin, the Middle East and Central Asia, with an estimated
600,000 – 1 million new cases occurring annually. In 2018, over 85% of new CL cases
occurred in ten countries: Afghanistan, Algeria, Bolivia, Brazil, Colombia, Iran (Islamic
Republic of), Iraq, Pakistan, the Syrian Arab Republic, and Tunisia.2 Finally, ML, the rarest
form of leishmaniasis, occurs mostly in Bolivia (the Plurinational State of), Brazil,
Ethiopia, and Peru.2

1.1.2 Current Leishmaniasis Treatments
Since each of the three leishmaniasis variants originate from infection via
Leishmania protozoans, the main goal of treatment is to eradicate the parasites while
not harming the host. The drugs typically used first when treating leishmaniasis are

2
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Figure 1.1. Heat map showing the worldwide presence of various Leishmania species.5

intravenous, intralesional, or intramuscular administration of pentavalent antimonials such
as sodium stibogluconate (1.1).3 If pentavalent antimonials are not available, then
intravenous administration of amphotericin B (1.2) is used, which is a polyenic antibody
with high antileishmanial activity.3 However, there are unfavorable characteristics
regarding both of these treatment methods. Pentavalent antimonials and amphotericin B
can be cardiotoxic and/or nephrotoxic, and both treatments come with a variety of negative
side effects ranging from muscle pain to vomiting (Table 1.1).3
More recent advances in leishmaniasis treatment have provided alternative methods
to the ones previously mentioned. Pentamidine (1.3), an aromatic diamine, is administered
intravenously or intramuscularly and has a treatment period of just one week, though
potential side effects include hypoglycemia and hyperglycemia.3 Miltefosine (1.4), a
choline, was originally an anticancer drug but was discovered to have antileishmanial
activity as well, with the added bonus of being able to be administered orally. 3 However,
Leishmania can quickly become resistant to miltefosine.3 Paromomycin (1.5) is an
interesting potential candidate for leishmanial treatment because it is administered
topically, unlike many of the other treatments. Unfortunately, this makes paromomycin
only applicable toward cutaneous leishmaniasis. Even against cutaneous leishmaniasis,
paromomycin’s large molecular weight and hydrophilic nature prevents it from permeating
human skin quickly.3 Another leishmaniasis-specific drug is sitamaquine (1.6), which
exclusively targets visceral leishmaniasis.3 Sitamaquine is a very recent drug and is still
undergoing clinical trials for oral use, although there is a lack of knowledge regarding the
toxicity of its metabolic.3 Nearly all current treatments for leishmaniasis have drawbacks
that prevent any one treatment from being the most efficient. It is to this end that either

4

new treatment strategies need to be developed or new antileishmanial drugs need to be
discovered. A larger selection of unique leishmanial drugs would provide greater versatility
in leishmaniasis treatment.

Sodium Stibogluconate (1.1)

Amphotericin B (1.2)
Pentamidine (1.3)

Miltefosine (1.4)

Paromomycin (1.5)
Sitamaquine (1.6)

Figure 1.2. Structures of various leishmaniasis treatments.
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Drugs

Administration
Routes

Amphotericin B Liposomal
Pentavalent
Miltefosine Paromomycin Pentamidine
Sitamaquine
deoxycholate amphotericin B
antimonials

Intravenous

Intravenous

Intramuscular,
Intramuscular,
intravenous or Intramuscular intravenous or
topic
intralesional

Oral

0.75-1 mg/kg
3-5 mg/kg
100-150
(15 or 20 days single dose or
Dosage
mg/day for
daily or
10-30 mg/kg
28 days
alternatively)
total dose
Primary
Highly effective Effective
Advantages
resistance is
and low toxicity and safe
unknown
Cost, poor
Need slow
Need slow
patient
intravenous
intravenous
compliance,
infusion,
infusion, high
Disadvantages
cannot be
toxicity,
cost, unstable
used in
unstable in high
in high
pregnant
temperatures temperatures
patients
Laboratory
strains,
Laboratory
Not
Resistance
some cases
strains
documented
reported in
India

Oral

15 mg/day for 3 mg/kg/day
21 days or 20 every other 20 mg/kg/day 2 mg/kg/day
mg/kg for 17
day for 4 for 28-30 days for 21 days
days
injections
Ease of
Short
Low cost
availablity and Effective
treatment
low cost
Length of
Efficacy varies
Efficacy varies
treatment,
between
between and
painful
Leishmania
within regions
injection and
species
toxicity

Laboratory
strains

Not
documented

Common

Toxicity

Not
documented

Table 1.1. Various treatments of leishmaniasis
and their relative advantages and disadvantages.3

1.2 Lyngbya majuscula
Development and discovery of medicinal treatments for most diseases is based on
combinatorial chemistry, which is the process of trying slightly varying chemicals on a
disease to see if any of the chemicals treat the disease exceptionally well. 6 This technique
works best when an initial chemical is discovered that has strong activity against the
disease, upon which further research can be done into optimizing that chemical’s activity
against the disease. Until that initial chemical is discovered however, combinatorial
chemistry can be difficult to properly utilize. Another approach to discovering disease
treatments is to isolate biological natural products from various organisms.6 This can either
lead to compounds that immediately exhibit strong activity against a disease or can provide
6

the starting chemical for combinatorial chemistry. Marine organisms must protect
themselves from the tremendous variety of environments and dangers they encounter, and
they do so by producing many cytotoxic chemicals as a makeshift immune system. These
cytotoxic chemicals are promising candidates for compound isolation.6 For example,
approximately half of anti-cancer discovery efforts, as of 2004, were based on marine
organisms.6 One of these marine organisms is called Lyngbya majuscula, which is a
tropical, filamentous cyanobacteria that has had over 110 metabolites identified as of 2004,
with 75% of them being biologically active in some way.6

1.2.1 Classes of Compounds Isolated from Lyngbya majuscula
Lyngbya majuscula synthesizes many different metabolites, and each of these
metabolites can be sorted into general classes based on the metabolites’ repeating units or
active regions. These classes include alkaloids, amides, amines, fatty acids, imidazoles,
lactones, lipopeptides, and malyngolides.7

1.2.2 Biologically Important Compounds from Lyngbya majuscula
Several biologically relevant compounds have been isolated from Lyngbya
majuscula, each with differing purposes and efficacies for said purpose. Examples of such
compounds are microcolin A (1.7), curacin A (1.8), and malyngamide F (1.9).7 Microcolin
A was found to have not only immunosuppressive activity, but also the ability to mediate
thymocyte apoptosis via a novel mechanism.7 Research also suggests that microcolin A
could be used as antineoplastic agents.7 Initial research into curacin A suggested that it had
substantial activity against proliferative cells, and further studies were done to examine

7

Microcolin A (1.7)

Curacin A (1.8)

Malyngamide F (1.9)
Figure 1.3. Structures of various compounds isolated from Lyngbya majuscula.

this quality in both curacin A and its analogs.7 The malyngamide class of compounds are
generally not bio-active, yet their presence in a wide variety of cyanobacteria strains around
the world suggests that their purpose has just not yet been identified.7
Another type of compound isolated from Lyngbya majuscula are lipopeptides,
which are short peptide sequences that have a carbon chain at one end of the molecule.
These compounds can be cyclic or acyclic and are generally extremely bioactive.7
Lipopeptides have an affinity for liposomes and cell membranes as well as a low molecular
weight, which explains the extreme cytotoxicity of lipopeptides.7 One such example of a
lipopeptide found in Lyngbya majuscula is called dragonamide E, which has been
discovered to have antileishmanial activity.8

8

CHAPTER 2
DRAGONAMIDE E AND RELATED COMPOUNDS

2.1 Dragonamide E
Dragonamide E (2.1) is a straight chain lipopeptide consisting of one phenylalanine
residue, three valine residues, and a carbon chain that contains an alkene and a terminal
alkyne. Additionally, each of the amino acid residues is N-methylated. Biologically
produced samples do not often contain terminal alkynes nor N-methylated amino acid
residues, so the presence of both functionalities in 2.1 is quite interesting.

Figure 2.1. Structure of Dragonamide E (2.1).

2.1.1 Isolation
In a research article presented in 2010 by Gerwick and coworkers, Lyngbya
majuscula was collected and processed via flash-phase chromatography to reveal that
certain portions of the elution had strong antileishmanial activity.8 After purification via
RP-SPE column chromatography and RP-HPLC, the resulting fraction contained two
compounds. Gerwick’s group determined that the major component of the fraction was
9

dragonamide A (2.2), and stated,
1

H and 13C NMR signals [were] indicative of phenylalanyl and valinyl residues,
along with a fatty acyl chain. Combined with a prominent [M+H]+ peak by APCIMS
at m/z 654, [this] data [was] fully consistent with literature values for the known
metabolite dragonamide A.8
The minor component of the fraction was a unique compound that needed to be
spectroscopically identified as well.

Figure 2.2. Structure of Dragonamide A (2.2).

2.1.2 Structure Elucidation
Initial investigation into this second metabolite’s structure revealed that it was
unprecedented in marine literature and that it was incredibly similar to dragonamide A,
including 1H NMR signals for a terminal NH2, an N-methyl phenylalanyl, and three Nmethyl valinyl residues, and

13

C NMR signals for a terminal alkyne.8 However,

dragonamide A possessed two more protons and one less degree of unsaturation than this
new compound. Analysis of the 1H NMR and 13C NMR signals revealed the presence of
an α, β unsaturated double bond between carbons C35 and C36 (Figure 2.3), providing the
sole distinction between dragonamide A and the new metabolite.8 This metabolite was
named “dragonamide E” (2.1) as it was the fifth compound in the dragonamide family to
have been isolated from Lyngbya cyanobacteria.8 The discovery of 2.1 was novel due to
how all of the other dragonamide compounds have a secondary methyl group with the (S)
absolute configuration at C35 or the equivalent position.8 The structure of dragonamide E
10

36
35

Figure 2.3. Structure of Dragonamide E (2.1) with C35 and C36 labeled.

suggests that it could be a precursor to other compounds in the dragonamide family, such
as dragonamide A (2.2).8

2.1.3 Biological Activity and Significance
After having isolated and characterized dragonamide E, Gerwick and coworkers set
out to determine the efficacy of 2.1 against various diseases. Dragonamide E was tested
against Plasmodium falciparum (malaria), Leishmania donovani (leishmaniasis), and
Trypanosoma cruzi (Chagas’ disease), with in vitro antileishmanial activity being the most
prominent with an IC50 = 5.1 µM.8 Ultimately, it is the high antileishmanial activity of 2.1
that makes it attractive as a potential leishmaniasis treatment and, thus, why it was pursued
in this study.

2.2 Similar Compounds to Dragonamide E
Many types of lipopeptides have been isolated from Lyngbya majuscula, each of
them having different efficacies against a variety of diseases.7 Observing the similarities
and differences between these and other lipopeptides could allow for insight as to which
parts of lipopeptides are crucial for cytotoxic activity in general, and which parts specialize
each lipopeptide for individual disease treatments.
11

2.2.1 Dragonamides
The dragonamide class of lipopeptides are characterized by a terminal alkyne
moiety attached to a tetrapeptide containing many valines. Each of the amino acids in the
tetrapeptide are N-methylated as well. Included in this class are dragonamides A–E (2.1–
2.5). The key factor in differentiating these compounds is the exact structure of the alkyne
moiety and the tetrapeptide sequence. Dragonamides A and E have a phenylalanine residue
at the C-terminus, whereas dragonamides B, C, and D have a fourth valine residue at that
position. This difference in amino acid sequence is crucial to the cytotoxic activity of the
compound. For instance, dragonamide A has good antimalarial and antileishmanial activity
(IC50 = 7.7 µM and 6.5 µM, respectively), but dragonamide B has no activity against either
disease, suggesting that the terminal phenylalanine residue is vital to the cytotoxic activity.9
Of the dragonamide compounds, dragonamide E has the best antileishmanial activity with
an IC50 of 5.1 µM.8

2.2.2 Dragomabin
Whereas there are multiple dragonamides, dragomabin (2.6) is the only compound
in its class. However, it is still a linear lipopeptide with an alkyne moiety attached to a
tetrapeptide. The key difference in dragomabin compared to the dragonamides is the
difference in amino acid sequence. Dragomabin also lacks the N-methylation on one of its
amino acid. While no antileishmanial IC50 has been reported for dragomabin, dragomabin’s
antimalarial IC50 is 6.0 µM.9 Additionally, the IC50 against Vero cells is quite large (IC50 =
182.3 µM) implying that dragomabin is highly selective against malaria over mammalian
cells, making dragomabin a good malaria treatment candidate.9

12

Dragonamide A (2.2)

Dragonamide B (2.3)

Dragonamide C (2.4)

Dragonamide D (2.5)

Dragonamide E (2.1)

Dragomabin (2.6)

Figure 2.4. Structures of Dragonamides A-E (2.1–2.5) and Dragomabin (2.6).
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2.2.3 Carmabins
The carmabins (2.7–2.8) are extremely similar to dragomabin, with the only
difference being the exact structure of the hydrophobic chain on the left side of the
molecule, herein referred to as the “hydrophobic tail”. Carmabin A in particular has similar
antimalarial activity as dragomabin (IC50 = 4.3 µM), but its IC50 for Vero cells is 9.8 µM,
indicating its cytotoxic properties are much stronger and less specific than dragomabin.9
This is presumably due to the longer and more branched alkyne moiety of the carmabins.9

Carmabin A (2.7)

Carmabin B (2.8)
Figure 2.5. Structures of Carmabins (2.7–2.8).

2.2.4 Almiramides
The almiramides (2.9–2.11) resemble the dragonamides the least of the related
compounds discussed so far, yet their antileishmanial activity rivals and even exceeds that
of the dragonamides.10 Almiramides are linear lipopeptides that feature five amino

14

Almiramide A (2.9)

Almiramide B (2.10)

Almiramide C (2.11)
Figure 2.6. Structures of Almiramides (2.9–2.11).

acid residues instead of the four seen previously. The additional amino acid is an alanine
found between the phenylalanine and valine residues; otherwise, the amino acid sequence
is the same as the dragonamides. The other notable distinctions are that the third amino
acid is not N-methylated and that the exact structure of the hydrophobic tail is slightly
different.
While almiramide A has no activity against Leishmania donovani, almiramide B
and C have an IC50 of 2.4 µM and 1.9 µM against Leishmania donovani respectively,
exceeding that of even dragonamide E (5.1 µM).8,10 This implies that there must be
unsaturation of some type at the end of the hydrophobic moiety for there to be
antileishmanial activity.10 In an almiramide discovery and development paper, Linington

15

and coworkers made various analogues to the almiramides in an effort to determine what
regions of the almiramides were crucial to their antileishmanial activity while also keeping
cytotoxicity toward mammalian cells low.10 The main takeaways from the testing were that
some type of unsaturation is needed at the edge of the hydrophobic moiety, all of the amino
acids should have their nitrogens methylated (unlike the standard almiramides), and that
the C-terminus of the peptide sequence should be capped by either an NH2 or an NMe2
group.10 These characteristics are already present in dragonamide E, making further
research into its antileishmanial activity all the more promising.

2.3 The Call for the Synthesis of Dragonamide E
While the research done by Gerwick and coworkers provided the basis for
dragonamide E and its potential use in the treatment of leishmaniasis, little has been
accomplished to that end since the initial publication in 2010.8 For this reason, research
was done into dragonamide E in hopes of developing a proper synthesis, as commercialized
isolation of dragonamide E from Lyngbya majuscula would be far too costly both in
economical and environment terms.6 This new synthesis route would make dragonamide
E much more available to researchers, providing a higher likelihood of researchers
discovering its antileishmanial mechanism.

2.3.1 Previous Syntheses of Dragonamides and Related Compounds
While there have not been any published syntheses of dragonamide E specifically,
there have been reports published for the synthesis of similar compounds. Carmabin A and
dragomabin were synthesized by Baijun Ye and coworkers in 2018 (Scheme 2.1), and
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37

35

Carmabin A (2.7) (n = 1, 35S, 37R or 35R, 37S)
Dragomabin (2.6) (n = 0, 35S)

37

35

2.12 (n = 1, 35S, 37R or 35R, 37S)
2.13 (n = 0, 35S)

4

2

+

2.14 (n = 1, 2S, 4R or 2R, 4S)
2.15 (n = 0, 2S)

2.16

Scheme 2.1. Retrosynthesis of carmabin A (2.7) and dragomabin (2.6).11
dragonamide A (known only as dragonamide at the time of the publication) was
synthesized by Chen and coworkers (Scheme 2.2).11–12 Each of these approaches focuses
on synthesizing the hydrophobic tail with a carboxylic acid group at the end that would
connect to the peptide sequence, then coupling this moiety to the modified amino acids
with a peptide bond.11–12 The synthesis for dragonamide E will bear a resemblance to this
general method.
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Dragonamide A (2.2)

2.17

+

2.18

2.19

Scheme 2.2. Retrosynthesis of dragonamide A (2.2).12

2.3.2 Dragonamide E Synthesis Goals
With the knowledge that dragonamide E has both prominent antileishmanial
activity and has not been explored as a potential treatment for leishmaniasis, research into
dragonamide E should provide invaluable results to leishmaniasis drug development. The
research accomplished with dragonamide E in this work were based on two goals. The first
was to develop a working synthesis for dragonamide E from relatively low-cost materials,
and the second was to use this synthesis to create a wide variety of dragonamide E
analogues (Table 2.1). While dragonamide E contained N-methylphenylalanine and Nmethylvaline residues, the analogues were planned to have various permutations of N-
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methylated amino acid residues and unmethylated residues to utilize in Structure-Activity
relationship (SAR) studies. The reason for planning to synthesize these analogues was to
discover if the N-methylation was beneficial to the antileishmanial activity. If any of the
analogues had significantly better or worse antileishmanial activity than the original
dragonamide E, then the antileishmanial mechanism of dragonamide E could potentially
be discovered by identifying the parts of the dragonamide E that are crucial to
antileishmanial activity and the parts that are not.
AA4

AA3

AA2

AA1

2.1
Amino Acid 1:
Amino Acid 2:
Amino Acid 3:
Amino Acid 4:

Dragonamide E
N-Me-L-Phe
N-Me-L-Val
N-Me-L-Val
N-Me-L-Val

Amino Acid 1:
Amino Acid 2:
Amino Acid 3:
Amino Acid 4:

Analogue 8
L-Phe
N-Me-L-Val
N-Me-L-Val
N-Me-L-Val

Amino Acid 1:
Amino Acid 2:
Amino Acid 3:
Amino Acid 4:

Analogue 16 Analogue 17
N-Me-L-Tyr
N-Me-L-Tyr
N-Me-L-Val
N-Me-L-Val
N-Me-L-Val
N-Me-L-Val
N-Me-L-Val
L-Val

Amino Acid 1:
Amino Acid 2:
Amino Acid 3:
Amino Acid 4:

Analogue 24 Analogue 25 Analogue 26 Analogue 27 Analogue 28 Analogue 29 Analogue 30 Analogue 31
L-Tyr
L-Tyr
L-Tyr
L-Tyr
L-Tyr
L-Tyr
L-Tyr
L-Tyr
N-Me-L-Val
N-Me-L-Val N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
L-Val
N-Me-L-Val
N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
N-Me-L-Val N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val

Analogue 1
N-Me-L-Phe
N-Me-L-Val
N-Me-L-Val
L-Val

Analogue 2
N-Me-L-Phe
N-Me-L-Val
L-Val
N-Me-L-Val

Analogue 3 Analogue 4 Analogue 5 Analogue 6 Analogue 7
N-Me-L-Phe N-Me-L-Phe N-Me-L-Phe N-Me-L-Phe N-Me-L-Phe
L-Val
N-Me-L-Val
L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val

Analogue 9 Analogue 10 Analogue 11 Analogue 12 Analogue 13 Analogue 14 Analogue 15
L-Phe
L-Phe
L-Phe
L-Phe
L-Phe
L-Phe
L-Phe
N-Me-L-Val N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
L-Val
N-Me-L-Val N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
Analogue 18
N-Me-L-Tyr
N-Me-L-Val
L-Val
N-Me-L-Val

Analogue 19 Analogue 20 Analogue 21 Analogue 22 Analogue 23
N-Me-L-Tyr N-Me-L-Tyr N-Me-L-Tyr N-Me-L-Tyr N-Me-L-Tyr
L-Val
N-Me-L-Val
L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val
L-Val
N-Me-L-Val
L-Val

Table 2.1. Planned analogues of dragonamide E (2.1).
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CHAPTER 3
TOWARD THE TOTAL SYNTHESIS OF DRAGONAMIDE E

3.1 Planned Synthetic Route for Dragonamide E
In the retrosynthetic analysis, dragonamide E (2.1) was treated as two separate
compounds: hydrophobic tail 3.1 and tetra amino acid head 3.2 (Scheme 3.1). Whereas 3.2
could be made via solid phase peptide synthesis (SPPS) using amino acid coupling
chemistry, synthesizing 3.1 would require a more involved approach.

2.1

+
3.1

3.2

Scheme 3.1. Retrosynthesis of dragonamide E (2.1).

3.1.1 Synthesis of Carboxylic Acid 3.1
The starting material for the synthesis of 3.1 was 1-pentyne (3.3). The alkyne was
20

1. n-BuLi, THF, –78 °C, 1 h

3.3

2. (CH2O)n, –78 °C, 1 h, rt, 22 h

3.4 (49%)

1. Li, H2NCH2CH2NH2,
80 °C, 1.5 h

2. t-BuOK,
rt, 0.5 h

IBX
EtOAc, 77 °C, 1 h

3.6

3.5 (32%)

3.8, NaH, THF,
0 °C → rt, 18 h
LiOH
THF, 75 °C, 24 h

3.9 (49%, two steps)

3.1 (76%, 9:1 E:Z)

P(OEt)3
160 °C, 10 h

3.7

3.8 (91%)

Scheme 3.2. Hydrophobic tail synthesis.

first deprotonated using n-butyllithium (n-BuLi) in tetrahydrofuran (THF) at –78 °C, then
underwent an alkynylation using paraformaldehyde to give primary alcohol 3.4 (Scheme
3.2).13 The alkynylation of 3.3 into 3.4 was easily the most cumbersome reaction of this
entire work. Prior to using the n-BuLi, it was titrated to determine its concentration in
solution. This ensured the correct amount of n-BuLi was used in the deprotonation of the
alkyne, as an excess amount of n-BuLi promotes side reactions. The titration techniques
used often suggested that the concentration of n-BuLi was far less concentrated than
expected, yet experimental observations implied that an excess of n-BuLi was being used.
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Considering that the highest yield for this reaction was a mere 49% with a notable presence
of 1-pentanol, the primary byproduct in this reaction, via TLC analysis, this reaction stands
to be improved the most. Ideally, a different set of reagents could be used for the
alkynylation which would remove the need for a supplementary titration to be performed
and thus improve the yield of this reaction.
Lithium metal was dissolved in ethylene-1,2-diamine at 80 °C, then treated with
potassium tert-butoxide (t-BuOK) in preparation for an alkyne zipper reaction. Alkynol 3.4
was added to the solution to result in primary alcohol 3.5.13 The alkyne zipper reaction of
3.4 into 3.5 was initially performed using NaH in ethylene-1,2-diamine, but the reaction
required significant temperature moderating and an extended reaction time.14 The lithium
metal and potassium tert-butoxide variant of the alkyne zipper reaction required much less
time investment due to performing the reaction at a constant elevated temperature with no
need for intervention. Unfortunately, this reaction was only performed on impure samples
of 3.4, so the percent yields may not properly reflect the efficiency of the reaction. Using
this method, the highest percent yield of 3.5 after purification was 32%, which was likely
influenced by the inaccurate mass determination of 3.4 prior to starting the reaction.
Performing this reaction with a pure sample of 3.4 would immediately provide better
insight into the efficiency of the reaction.
Alcohol 3.5 was then stirred in ethyl acetate (EtOAc) alongside solid 2iodoxybenzoic acid (IBX) under reflux to oxidize the alcohol into aldehyde 3.6.15 The
oxidation of 3.5 into 3.6 required testing multiple different reaction conditions with varying
levels of success. Initially, Dess–Martin periodinane (DMP) was used to attempt the
oxidation, but the reaction never fully progressed.16 The second oxidation method tested
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utilized the Swern oxidation with oxalyl chloride, triethylamine, and dimethylsulfoxide
(DMSO).17 While this reaction produced aldehyde 3.6 in good crude yields (80%), the need
of dry ice/acetone bath temperatures and multiple washes and extractions along with the
presence of malodorous dimethyl sulfide as a side product reduced the desirability of the
method. The last reaction tested utilized solid IBX suspended in ethyl acetate heated under
reflux. Not only did this produce the aldehyde in similar crude yields as the Swern
oxidation, but the workup steps were incredibly simple. Any solid byproducts and excess
IBX were filtered away and the ethyl acetate was removed in vacuo to yield crude 3.6.
Ultimately, the use of IBX was the clear choice for the oxidation of alcohol 3.5 into
aldehyde 3.6.
Triethyl-2-phosphonopropionate (3.8) was prepared via a Michaelis–Arbuzov
reaction by heating ethyl-2-bromopropionate (3.7) and triethylphosphite at 160 °C, while
distilling the bromoethane byproduct.18 The Michaelis–Arbuzov reaction to produce
phosphonate 3.8 was easily the most successful reaction of this entire work. Ethyl-2bromopropionate (3.7) and triethylphosphite reacted together with no need for a solvent,
and the reaction flask was connected to a distillation apparatus to remove bromoethane as
it was being produced in the reaction. A separate distillation to purify phosphonate 3.8 gave
a respectable 91% yield upon its completion.
Phosphonate 3.8 was used in a Horner–Wadsworth–Emmons (HWE) reaction with
aldehyde 3.6 in THF to give ester 3.9.19 When performing the HWE reaction between
aldehyde 3.6 and phosphonate 3.8, 3.6 was used in its crude state without further
purification. The actual reaction process was quite simple and gave 3.9 in a fair yield (49%
over two steps).
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While the HWE reaction was one of the pivotal points for synthesizing 3.1, there
was initial uncertainty if phosphonate 3.8 should undergo hydrolysis to give a carboxylic
acid (3.10) prior to the HWE reaction, and then give 3.1 immediately after the HWE
reaction upon workup (Scheme 3.3).20 While the synthesis of 3.10 went smoothly, its
viscosity was such that it was incredibly cumbersome to work with, especially when using
syringes. This led to the ester hydrolysis step being performed after the HWE reaction with
phosphonate 3.8 instead of before it.

NaOH
0 °C, 3.5 h

3.8

3.10 (87%)

Scheme 3.3. Synthesis of carboxylic acid functional group prior to HWE olefination.

Finally, hydrolysis of 3.9 with lithium hydroxide (LiOH) under reflux in aqueous
THF gave carboxylic acid 3.1.21 The hydrolysis of 3.9 into 3.1 initially appeared to be a
simple reaction but had an unforeseen result. While the literature suggested reacting 3.9 at
0 °C, it was instead observed that refluxing the reaction greatly improved reaction times as
verified by TLC analysis.21 However, a surprising result was that 1H NMR and 13C NMR
analysis of 3.1 showed an isomerization of the alkene had occurred with a 9:1 E:Z ratio in
all experimental results. This reaction was performed separately at both ambient and reflux
temperatures with identical 1H NMR and 13C NMR patterns, so it was concluded that the
temperature did not cause the isomerization. Instead, it is hypothesized that the basic
conditions of the reaction promoted the isomerization by removing a particularly acidic
hydrogen from 3.8, causing a shift in electrons to allow the previously double-bonded
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carbons to freely rotate (Scheme 3.4). A potential workaround for this issue would be to
use an acidic environment for the hydrolysis instead, as that would prevent any basemediated isomerization while still promoting the primary reaction.

180°

3.11

3.1

3.12

3.11

Scheme 3.4. Proposed mechanism for the E/Z isomerization of 3.1 to 3.12.

3.1.2 Synthesis of Modified Amino Acids 3.12–3.15
Modification of both L-valine (3.13) and L-phenylalanine (3.14) followed the same
general procedures. For the first step, each of the amino acids were introduced to the
fluorenylmethyloxycarbonyl (Fmoc) protecting group, specifically with the use of N-(9fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu), which would eventually be used
to protect the amine group during the coupling reactions. Each amino acid and Fmoc-OSu
were dissolved in acetone in a basic environment to produce amino acids 3.15 and 3.16
(Scheme 3.5).22 Adding the Fmoc protecting group to both L-valine and L-phenylalanine
went smoothly with yields being 67% and 61%, respectively.
Since some of the planned dragonamide E analogues contained unmethylated
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R

R

Fmoc-OSu

2. TFA, Et3SiH,
DCM, 22 h

NaHCO3, acetone

3.13 (R = i-Pr)
3.14 (R = CH2Ph)

R

1. (CH2O)n, p-TsOH,
toluene, 110 °C, 1 h

3.15 (R = i-Pr)
3.16 (R = CH2Ph)

3.17 (R = i-Pr)
3.18 (R = CH2Ph)

Scheme 3.5. Synthesis of the N-methylated amino acids.
amino acids, half of the synthesized 3.15 and 3.16 was stored for later use, while the other
half was used in the next steps. The next reaction was to treat the Fmoc-protected amino
acid with paraformaldehyde and a catalytic amount of para-toluenesulfonic acid (p-TsOH)
in toluene under reflux to generate an oxazolidinone. This functional group was then
cleaved using trifluoroacetic acid (TFA) and triethylsilane (Et3SiH) in dichloromethane
(DCM) to generate N-methylated Fmoc-protected amino acids 3.17 and 3.18.23 The Nmethylation step for the amino acids was more troublesome. Regarding valine, while the
reaction overall was a success, the yield was low (28%). Phenylalanine proved to be the
bigger problem however, as toward the end of the workup steps, most of the solvated 3.18
would turn into a viscous, sticky oil that was cumbersome to work with upon rotary
evaporation. Eventually some of 3.18 was obtained as a white powder (37%), but not
without additional efforts to separate the remaining solvated 3.18 from the portion that
turned into the viscous oil.

3.1.3 Initial Plan to Combine 3.1 and 3.2
Once ample amounts of 3.1, 3.17, and 3.18 were synthesized, the hydrophobic tail
and tetra amino acid head could be linked to form the final dragonamide E product.
However, the coupling process did not go according to plan and required modification. The
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initial procedure was to couple amino acid 3.18 to Rink amide resin in a two-step process.
First, piperidine would be used to deprotect the resin, then the coupling would be
accomplished using hydroxybenzotriazole (HOBt), O-(benzotriazol-1-yl)-N,N,N’,N’tetramethyluronium hexafluorophosphate (HBTU), and N,N-diisopropylethylamine
(DIPEA) to produce the intermediate amino acid 3.19 (Scheme 3.6).24 Amino acid 3.17
could be coupled three sequential times using the same reaction conditions (Scheme 3.6,
ii), using five equivalents of each of the reagents instead of the previous three equivalents
as well as the utilization of O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HATU) instead of HBTU (3.20, 3.21, 3.2).24 Finally, 3.1 could be
added using the same conditions as the 3.17 additions (Scheme 3.6, iii) to give dragonamide
E tethered to the Rink amide resin (3.22). Dragonamide E could then be cleaved off the
resin.24
The coupling of the N-methylated amino acids revealed a flaw with the initial
retrosynthesis reasoning. Amino acid 3.18 was successfully linked to the Rink amide resin
as per the initial procedure and was verified with a Kaiser test. The problems arose when
3.17 was introduced to the resin. Because all the amino acids in dragonamide E are Nmethylated, each of the amino acids used in the coupling must also be N-methylated. Thus,
the amines are secondary rather than primary, which drastically reduces the coupling
reactivity of the amino acids. The first addition of 3.17 took six hours to complete, but the
second addition was not complete even fourteen hours after the start of the reaction, as the
chloranil test used for reaction verification always gave a positive result, indicating that the
reaction was not complete. This ultimately brought the synthesis of dragonamide E to a
halt. However, there may be a simple solution to this situation. The Fmoc-N-methyl amino
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ii

i

3.20

3.19

3.18

ii

ii

3.21

3.2
iii

3.22
(i) 1. Rink Amide resin (100-200 mesh), piperidine, DMF, 40 min; 2. HOBt,
HBTU, DIPEA, 2 h; (ii) 1. piperidine, DMF, 40 min; 2. HOBt, HATU, DIPEA,
3.17, 6 h; (iii) 1. piperidine, DMF, 40 min; 2. HOBt, HATU, DIPEA, 3.1, 6 h

Scheme 3.6. Planned amino acid coupling reactions and conditions.

acids could have their carboxylic acids converted into the much more reactive acyl
chlorides. This would require one more step in the synthesis, with no added purification,
but the increased reactivity from the acyl chlorides would greatly reduce the coupling
reaction times.
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3.2 Summary and Future Advancements
While neither dragonamide E nor any of its analogues were directly synthesized in
this work, many important steps have been made toward accomplishing this goal. With the
main synthesis route now established, optimizing each reaction individually will culminate
into a reliable synthesis of dragonamide E. The synthesis framework could then potentially
branch out to create other lipopeptides generated by Lyngbya majuscula.
The most obvious plan for future endeavors in this synthetic field is to put the
previously mentioned changes into effect and observe any new developments that arise.
Optimizing existing reactions such as the alkynylation and ester hydrolysis would lead to
a more confident total synthesis. Additionally, once the dragonamide E synthesis route is
realized, the SAR studies into unmethylated amino acids in dragonamide E can commence.
This will provide insight into whether dragonamide E may potentially become one of the
newest drugs for leishmaniasis treatment.
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CHAPTER 4
EXPERIMENTAL DETAILS

General Methods: Unless otherwise stated, all oxygen and moisture-sensitive
reactions were performed under anhydrous conditions by use of argon-charged glassware.
Solutions and solvents sensitive to moisture were transferred using standard syringe
techniques. All commercial reagents were purchased as reagent grade and used without
further purification. All organic solvents were used dry: tetrahydrofuran (THF), diethyl
ether (Et2O), dichloromethane (CH2Cl2), and toluene were purified via a Pure Solv MD-7
Solvent Purification System. Thin-layer chromatography was performed using Silicycle
Glass Backed TLC Extra Hard 60 Å, 250 µm F-254 TLC plates that were visualized by panisaldehyde (PAA), cerium ammonium molybdate (CAM), and potassium permanganate
(KMnO4) staining. Column chromatography was performed using Silicycle SiliaFlash P60
Silica gel. Nuclear Magnetic Resonance (NMR) spectra were obtained for proton (1H) and
carbon (13C) nuclei using a Varian AS400 NMR spectrometer; residual solvent peak signals
for CDCl3 were set at 7.26 and 77.16 ppm in the 1H and 13C spectra, respectively. A Nicolet
iS10 smart iTR spectrometer was used to record infrared spectra and absorptions are
reported in reciprocal centimeters.
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Alcohol 3.4
1. n-BuLi, THF, –78 °C, 1 h

3.3

2. (CH2O)n, –78 °C, 1 h, rt, 22 h

3.4 (49%)

1-Pentyne (3.3, 50.0 mL, 0.507 mol) and THF (500 mL) were added to an argoncharged 2-L round bottomed flask. The flask was cooled to –78 °C with a dry ice/acetone
bath, and the n-BuLi (270 mL, 0.512 mol) was added via syringe at a rate of 11 mL/min.
The solution was stirred for 1 h. The paraformaldehyde (16.74 g, 0.557 mol) was added
and the mixture continued to stir for 22 h. Ammonium chloride (saturated, 250 mL) was
added to quench the reaction. Et2O (1,600 mL) and H2O (800 mL) were added to the
solution in four portions. Each portion was put into a 2-L separatory funnel and the aqueous
and organic layers were separated. The combined aqueous layer was extracted with Et2O
(3 x 375 mL). The combined organic layer was washed with brine (750 mL), dried over
MgSO4, filtered, and concentrated via rotary evaporation. The resulting oil was distilled
under reduced pressure to give 3.4 (24.44 g, 49.11%) as a colorless oil; Rf = 0.43 (4:1
hexanes:ethyl acetate, v/v); IR (neat) 3311, 2961, 2933, 2873, 2289, 2227, 1726, 1457,
1379, 1338, 1277, 1239, 1137, 1033, 1005, 867, 633 cm–1. Other spectroscopic data
matched the literature.13

Alcohol 3.5
1. Li, H2NCH2CH2NH2, 80 °C, 1.5 h
2. t-BuOK, rt, 0.5 h

3.5 (32%)

3.4

A lithium rod (0.44 g, 63.0 mmol) and ethylene-1,2-diamine (40 mL) were placed
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in an argon-charged 100-mL three neck flask at 80 °C and stirred for 1.5 h. The solution
was cooled to rt naturally and t-BuOK (4.52 g, 40.3 mmol) was added and stirred for 30
min. 2-hexyn-1-ol (3.4, 1.01 g, 10.32 mmol) was syringed into the flask over 5 min and
stirred for 2.5 h. The purple solution was poured into a 250-mL separatory funnel along
with ice water (40 mL), then Et2O (60 mL) once the heat dissipated. The layers were
separated and the aqueous layer was extracted with Et2O (3 x 20 mL). The combined
organic layer was washed with 1 M HCl (2 x 16 mL), saturated NaHCO3 (16 mL), and
brine (16 mL). The organic layer was dried over MgSO4, filtered, and concentrated via
rotary evaporation. The resulting oil was purified via column chromatography with a 4:1
hexanes:ethyl acetate solvent. 3.5 (0.32 g, 31.93%) was obtained as a colorless oil; Rf =
0.21 (4:1 hexanes:ethyl acetate, v/v); IR (neat) 3294, 2940, 2867, 2116, 1455, 1434, 1329,
1161, 1059, 989, 937, 629 cm–1. Other spectroscopic data matched the literature.13

2-Iodoxybenzoic Acid (IBX) 4.2

Oxone, H2O, 70 °C , 3.5 h

4.2 (94%)

4.1

2-Iodobenzoic acid (50.21 g, 0.202 mol), oxone (166.54 g, 0.267 mol), and H2O
(650 mL) were added to a 2-L round bottomed flask with a reflux condenser attached. The
flask was stirred and heated to 70 °C over 20 min, then stirred for 3 h. The flask was
removed from the oil bath, cooled to rt, then put in a cold-water bath and stirred for 1.5 h.
The flask’s contents were poured over a medium-grade fritted funnel and the solid was
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washed with H2O (6 x 100 mL) and acetone (2 x 100 mL). The solid (4.2, 53.08 g, 93.84%)
was dried overnight and obtained as a white powder. It was used immediately.

Phosphonate 3.8
P(OEt)3
160 °C, 10 h

3.8 (91%)

3.7

Ethyl-2-bromopropionate (3.7, 65.0 mL, 0.500 mol) and P(OEt)3 (86.0 mL, 0.506
mol) were put into a 250-mL round bottomed flask with a distillation head attached. The
reaction was heated at 160 °C for 10 h, during which time the bromoethane was distilled.
After the 10 h, the flask was connected to a distillation apparatus under reduced pressure
to purify triethyl-2-phosphonopropionate (3.8, 108.03 g, 90.70%) as a fragrant colorless
oil; Rf = 0.15 (4:1 hexanes:ethyl acetate v/v); IR (neat) 2983, 2942, 2909, 1732, 1457,
1392, 1368, 1314, 1252, 1179, 1162, 1094, 1017, 958, 904, 860, 803 cm–1. Other
spectroscopic data matched the literature.18

Phosphonic Acid 3.10
NaOH
0 °C, 3.5 h

3.8

3.10 (87%)

Triethyl-2-phosphonopropionate (3.8, 18.41 g, 77 mmol) and H2O (30 mL) were
added to a 200-mL round bottomed flask. The solution was stirred and cooled to 0 °C, then
10 M NaOH (8.00 mL, 80 mmol) was added and stirred for 1 h. The reaction was warmed
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to rt and stirred another 2.5 h. The reaction was cooled to 0 °C again and acidified with
HCl (concentrated) until pH ≤ 1. The reaction was brought to rt and saturated with NaCl.
The mixture was extracted with DCM (3 x 25 mL), dried over MgSO4, filtered, and
concentrated via rotary evaporation to give 3.10 (14.21 g, 87.45%) as a clear yellow-tinted
oil. IR (neat) 2984, 2942, 2572, 1732, 1458, 1393, 1294, 1176, 1016, 964, 856, 817, 735,
693 cm–1. Other spectroscopic data matched the literature.20

Ester 3.9
1. IBX, EtOAc, 77 °C, 4 h

2. NaH, THF, 3.8, 0 °C → rt, 18 h

3.5

3.9 (49% over two steps)

5-hexyn-1-ol (3.5, 9.00 g, 91.7 mmol) and EtOAc (650 mL) were added to a 1-L
round bottomed flask with a reflux condenser. After having dissolved, IBX (77.60 g, 275.2
mmol) was added and heated to 77 °C and stirred for 5 h with TLC verification. The
mixture was then cooled to rt and filtered through a medium-fritted funnel. The solid was
washed with EtOAc (3 x 100 mL). The combined filtrate was concentrated via rotary
evaporation to give crude 5-hexynal (3.6), which was used immediately.
A separate 1-L round bottomed flask was charged with argon, NaH (4.40 g, 110
mmol), and THF (375 mL) at 0 °C. Phosphonate 3.8 (28.38 g, 119 mmol) was then added
and stirred for 18 h, during which the reaction warmed to rt. Crude aldehyde 3.6 (supposed
8.82 g, 92 mmol) was syringed into the flask and stirred at rt for 2 h. The solution was put
into a 1-L separatory funnel, followed by H2O (100 mL), then Et2O (100 mL). The aqueous
phase was removed and the organic phase was washed with H2O (3 x 60 mL). The
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combined aqueous phase was extracted with DCM (2 x 60 mL). The combined organic
phase was washed with brine (120 mL), dried over MgSO4, filtered, and concentrated via
rotary evaporation. The resulting oil was purified over a column chromatography with 19:1
hexanes:ethyl acetate solvent. 3.9 (8.09 g, 48.95% over two steps) was obtained as a
fragrant colorless oil; Rf = 0.64 (4:1 hexanes:ethyl acetate v/v); 1H NMR (400 MHz,
CDCl3) δ 6.65 (m, 1H), 4.11 (q, J = 7.2 Hz, 2H), 2.23 (app q, J = 7.2 Hz, 2H), 2.15 (td, J
= 6.8, 2.4 Hz, 2H), 1.91 (t, J = 2.8 Hz, 1H), 1.78 (s, 3H), 1.60 (quint, J = 7.2 Hz, 2H), 1.22
(t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.0, 140.7, 128.7, 83.7, 68.9, 60.4,
27.4, 27.3, 18.0, 14.2, 12.3; IR (neat) 3299, 2981, 2935, 2867, 2118, 1705, 1651, 1446,
1389, 1367, 1256, 1210, 1175, 1118, 1082, 1037, 869, 743, 631 cm–1.

Carboxylic Acid 3.1
LiOH
THF, 75 °C, 24 h

3.1 (76% 9:1 E:Z)

3.9

Ethyl-(2E)-2-methyl-2-octen-7-ynoate (3.9, 8.09 g, 44.9 mmol) and THF (45 mL)
were put into a 1-L round bottomed flask. 2 M LiOH was added (45.0 mL, 90 mmol) and
the contents were heated under reflux at 75 °C for 24 h with TLC verification. The solution
was put into a 500-mL separatory funnel, diluted with H2O (90 mL), then washed with
DCM (2 x 135 mL). After acidifying the aqueous layer with 1 M HCl until pH ≤ 2, the
aqueous layer was extracted with EtOAc (3 x 135 mL). The combined EtOAc was washed
with brine, dried over MgSO4, filtered, and concentrated via rotary evaporation. The
slightly yellow oil was purified over a column chromatography with 7:1 hexanes:ethyl
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acetate to give carboxylic acids 3.1 (5.22 g, 76.41%) in a 9:1 E/Z ratio; Rf = 0.36 (4:1
hexanes:ethyl acetate v/v); 1H NMR (400 MHz, CDCl3) for E isomer (3.1, major): δ 11.96
(s, 1H), 6.86 (m, 1H), 2.31 (app q, J = 7.6 Hz, 2H), 2.19 (td, J = 6.8, 2.4 Hz, 2H), 1.96 (t,
J = 2.8 Hz, 1H), 1.82 (d, J = 0.8 Hz, 3H), 1.66 (quint, J = 7.2 Hz, 2H);

13

C NMR (100

MHz, CDCl3) for E isomer (3.1, major): δ 173.9, 143.9, 128.1, 83.6, 69.1, 27.7, 27.2, 18.1,
12.0; 13C NMR (100 MHz, CDCl3) for Z isomer (minor): δ 173.9, 145.2, 127.2, 84.1, 68.7,
28.9, 28.3, 20.5, 18.2; IR (neat) 3299, 2934, 2665, 2118, 1682, 1641, 1419, 1388, 1277,
1184, 1130, 1087, 933, 798, 744, 632 cm–1.

Fmoc-protected L-Valine (3.15)

Fmoc-OSu
NaHCO3, acetone

3.13

L-valine (3.13,

3.15 (67%)

29.29 g, 0.250 mol) was dissolved in H2O (940 mL) in a 3-L round

bottomed flask. Fmoc-OSu (85.83 g, 0.254 mol), NaHCO3 (22.08 g, 0.263 mol), and
acetone (940 mL) were all added and stirred at rt until clear. The solution was then acidified
with 10% NaHSO4 solution (1,640 mL), which caused the product to precipitate. The solid
was filtered, washed with H2O (3 x 100 mL), and dried. The clumpy solid was
recrystallized by dissolving it in a minimal amount of boiling EtOAc, then adding enough
hexanes to begin recrystallization. The heat was removed and the flask was brought to rt
with no stirring. The flask was put into an ice bath for 10 min. Filtration and drying of the
product gave 3.15 (57.25 g, 67.46%) as a white powder. Spectroscopic data was consistent
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with that in the literature.25
Fmoc-protected L-Phenylalanine (3.16)

Fmoc-OSu
NaHCO3, acetone

3.14

L-phenylalanine

3.16 (61%)

(3.14, 41.32 g, 0.250 mol) was dissolved in H2O (940 mL) in a 3-

L round bottomed flask. Fmoc-OSu (85.95 g, 0.255 mol), NaHCO3 (21.74 g, 0.259 mol),
and acetone (940 mL) were all added and stirred at rt until clear. The solution was then
acidified with 10% NaHSO4 solution (1,640 mL), which caused the product to precipitate.
The solid was filtered, washed with H2O (3 x 100 mL), and dried. The clumpy solid was
recrystallized by dissolving it in a minimal amount of boiling EtOAc, then adding enough
hexanes to begin recrystallization. The heat was removed and the flask was brought to rt
with no stirring. The flask was put into an ice bath for 10 min. Filtration and drying of the
product gave 3.16 (59.07 g, 60.99%) as a white powder. Spectroscopic data was consistent
with that in the literature.22

Fmoc-N-methylvaline (3.17)

1. (CH2O)n, p-TsOH, toluene, 110 °C, 1 h
2. TFA, Et3SiH, DCM, 22 h

3.17 (28%)

3.15
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Fmoc-L-valine (3.15, 29.01 g, 80 mmol) was put into a 2-L round bottomed flask
and suspended in toluene (300 mL). Paraformaldehyde (16.75 g, 558 mmol) and a catalytic
amount of p-TsOH (1.29 g, 6.80 mmol) were added and heated under reflux with a Dean–
Stark trap attached for azeotropic water removal for 1 h. The solution was cooled to rt,
washed with 1 M NaHCO3 (3 x 200 mL), dried with MgSO4 filtered, and concentrated via
rotary evaporation as a viscous golden oil.
The oil was then dissolved in DCM (22 mL) in an argon-charged flask.
Trifluoroacetic acid (22 mL, 297 mmol) and Et3SiH (5.32 mL, 33.4 mmol) were added and
stirred at rt for 22 h. Compressed air was blown over the flask to evaporate the TFA and
Et3SiH. Once concentrated, the golden oil was dissolved in toluene (75 mL) and
subsequently removed by rotary evaporation. This was done three times. The solid was
then recrystallized in a solution of 1:1 Et2O:EtOAc to give 3.17 (8.56 g, 28.40%) as a white
powder. Spectroscopic data was consistent with that in the literature.23

Fmoc-N-methylphenylalanine (3.18)

1. (CH2O)n, p-TsOH, toluene, 110 °C, 1 h
2. TFA, Et3SiH, DCM, 22 h

3.18 (37%)

3.16

Fmoc-L-phenylalanine (3.16, 19.40 g, 50.06 mmol) was put into a 2-L round
bottomed flask and suspended in toluene (1,000 mL). Paraformaldehyde (10.07 g, 335
mmol) and a catalytic amount of p-TsOH (0.54 g, 2.83 mmol) were added and heated under
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reflux with a Dean Stark trap attached for azeotropic water removal for 1 h. The solution
was cooled to rt, washed with 1 M NaHCO3 (3 x 200 mL), dried with MgSO4 filtered, and
concentrated via rotary evaporation as a viscous golden oil.
The oil was then dissolved in DCM (150 mL) in an argon-charged flask.
Trifluoroacetic acid (150 mL) and Et3SiH (24.0 mL, 151 mmol) were added and stirred at
rt for 22 h. Compressed air was blown over the flask to evaporate the TFA and Et3SiH.
Once concentrated, the golden oil was dissolved in Et2O (50 mL) and subsequently
removed by rotary evaporation. This was done three times. The solid was precipitated with
hexanes (400 mL). A white solid formed at first, followed by a viscous, sticky oil. The
liquid was decanted off and concentrated via rotary evaporation, then dried under reduced
pressure to give 3.18 (7.45 g, 36.70%) as a white powder. Spectroscopic data was
consistent with that in the literature.23
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APPENDIX A:
1H

NMR SPECTRA
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44

1

H NMR Spectrum of 3.9 (400 MHz, CDCl3)
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1

H NMR Spectrum of 3.1 (400 MHz, CDCl3)
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Zoomed in 1H NMR Spectrum of 3.1 to show E/Z isomeric ratio (400 MHz, CDCl3)

APPENDIX B:
13C

NMR SPECTRA
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48

C NMR Spectrum of 3.9 (100 MHz, CDCl3)
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49

C NMR Spectrum of 3.9 (100 MHz, CDCl3, mixture of E/Z isomers)
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